Inactive Instrument

Other languages Stealth BioTherapeutics Corp

Equities

MITO

US85789A1051

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Stealth BioTherapeutics Corp Highlights Opportunities and Challenges in Ultra-Rare Disease Drug Development at World Orphan Drug Congress USA	23-06-14
Stealth BioTherapeutics Announces Positive End-Of-Phase 2 Meeting with FDA on the Development of Elamipretide in Patients with Dry Age-related Macular Degeneration	23-06-12
Stealth Biotherapeutics Enters into Exclusive Licensing Agreement with Pharmanovia to Commercialize Elamipretide	23-05-30
J. Wood Capital Advisors LLC and Morningside Venture (I) Investments Limited completed the acquisition of 22.5293% stake in Stealth BioTherapeutics Corp.	22-11-15
Stealth BioTherapeutics Corp Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis	22-11-01
Stealth BioTherapeutics Chief Financial Officer Departs	22-10-03
Stealth BioTherapeutics Corp Agrees to Go Private; Shares Jump	22-08-01
Stealth BioTherapeutics Gets Notice of Potential Delistment From Nasdaq	22-07-12
Sector Update: Health Care Stocks Climb Pre-Bell Tuesday	22-06-14
Sector Update: Health Care	22-06-14
Stealth BioTherapeutics Gets FDA Meeting on Pre-Application for Potential Barth Syndrome Treatment	22-06-14
Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome	22-06-14
Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium	22-06-08
Stealth BioTherapeutics Gets European Medicines Agency Orphan Drug Designation for Elamipretide	22-05-31
Stealth BioTherapeutics Corp Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide in Geographic Atrophy at the Clinical Trials at the Summit Meeting 2022	22-05-23
Stealth BioTherapeutics Gets FDA's Orphan Drug Designation for Duchenne Muscular Dystrophy Drug Candidate; Shares Rise	22-05-12
Stealth BioTherapeutics' Phase 2 Eye Disease Trial Fails to Meet Primary Endpoints; Shares Fall	22-05-02
Stealth Biotherapeutics Announces Data from Reclaim-2 Phase 2 Trial of Elamipretide in Geographic Atrophy	22-05-02
Stealth BioTherapeutics Corp Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-07
Stealth BioTherapeutics Corp Auditor Raises 'Going Concern' Doubt	22-04-06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Stealth BioTherapeutics Corp

Equities

MITO

US85789A1051

Other languages

Filters